Literature DB >> 7845151

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.

Y Benhamou, E Dohin, F Lunel-Fabiani, T Poynard, J M Huraux, C Katlama, P Opolon, M Gentilini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7845151     DOI： 10.1016/s0140-6736(95)90388-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

1.  Hepatitis B.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

2.  Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks.

Authors:  P Rajagopalan; F D Boudinot; C K Chu; B C Tennant; B H Baldwin; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation.

Authors:  J I Herrero; J Quiroga; B Sangro; I Sola; J I Riezu-Boj; F Pardo; J Prieto
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

4.  Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients.

Authors:  Fumi Umeoka; Yoshiaki Iwasaki; Masayuki Matsumura; Akinobu Takaki; Haruhiko Kobashi; Masashi Tatsukawa; Hidenori Shiraha; Shin-ichi Fujioka; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

5.  Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1.

Authors:  E A Santos; C F T Yoshida; V C Rolla; J M Mendes; I F Vieira; J Arabe; S A Gomes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

6.  YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation.

Authors:  Fei Pei; Jun-Yu Ning; Jiang-Feng You; Jing-Pin Yang; Jie Zheng
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

7.  Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.

Authors:  L T Martin; E Cretton-Scott; R F Schinazi; X J Zhou; H M McClure; C Mathe; G Gosselin; J L Imbach; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors:  K P Fischer; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 9.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

Review 10.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.